Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

Reviewing treatment options and outcomes for older patients with classic Hodgkin lymphoma

Reviewing treatment options and outcomes for older patients with classic Hodgkin lymphoma

Posted by on Oct 9, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated treatment options and outcomes for older patients with classic Hodgkin lymphoma (HL). This study concluded that conventional chemotherapy regimens remain a standard of care for these patients. Some background Chemotherapy remains the standard first-line treatment for cHL. One of the most commonly used regimens...

Read More

Does radiotherapy reduce the risk of recurrence in patients with early-stage Hodgkin lymphoma?

Does radiotherapy reduce the risk of recurrence in patients with early-stage Hodgkin lymphoma?

Posted by on Sep 12, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at whether radiotherapy had an impact on the recurrence rate in patients with early-stage Hodgkin lymphoma (HL). It found that in patients with early-stage HL who responded fully to chemotherapy, the addition of radiotherapy reduced the risk of localized recurrence.  Some background Early-stage...

Read More

Does radiotherapy increase the risk of heart disease in patients with Hodgkin lymphoma?

Does radiotherapy increase the risk of heart disease in patients with Hodgkin lymphoma?

Posted by on Sep 5, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the 30-year risk of heart disease in patients with Hodgkin lymphoma (HL) treated with radiotherapy. It found that radiotherapy led to a small increase in the risk of death from heart disease or stroke in these patients.  Some background HL is often treated with a combination of chemotherapy and...

Read More

Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.

Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.

Posted by on Aug 22, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of pembrolizumab (Keytruda) plus GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) as second-line therapy for patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the pembrolizumab plus GVD combination is safe and highly effective...

Read More

Can a combination of brentuximab vedotin and salvage chemotherapy treat classical Hodgkin’s lymphoma not responding to standard treatment?

Can a combination of brentuximab vedotin and salvage chemotherapy treat classical Hodgkin’s lymphoma not responding to standard treatment?

Posted by on Aug 15, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the combination of brentuximab vedotin (BV; Adcetris) and ICE salvage chemotherapy with ifosfamide (Ifex), carboplatin (Paraplatin), and etoposide (Etopophos) for the treatment of relapsing or refractory Hodgkin lymphoma (HL). This study showed that BV-ICE was a good salvage treatment option for...

Read More

Evaluating the long-term outcomes of patients with HL receiving intensified treatment

Evaluating the long-term outcomes of patients with HL receiving intensified treatment

Posted by on Jul 31, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate the long-term effectiveness and safety of high-dose chemotherapy (HDC) for the treatment of patients with unfavorable Hodgkin lymphoma (HL). The authors concluded that HDC increased the control of the disease in the long-term. Some background HDC with radiotherapy is a standard treatment of HL. 4 cycles of...

Read More

How does brentuximab vedotin perform long-term for advanced Hodgkin lymphoma?

How does brentuximab vedotin perform long-term for advanced Hodgkin lymphoma?

Posted by on Jul 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study presents 5-year results for the targeted antibody therapy brentuximab vedotin (BV; Adcetris) for patients with advanced Hodgkin lymphoma (HL) who had not been previously treated. It found that BV with chemotherapy led to less recurrence of HL compared to chemotherapy alone. Some background The outcomes for patients with the...

Read More

Is changing treatment intensity after PET scan effective over the long-term for patients with advanced-stage Hodgkin lymphoma?

Is changing treatment intensity after PET scan effective over the long-term for patients with advanced-stage Hodgkin lymphoma?

Posted by on Jul 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety outcomes of changing treatment intensity after a PET scan for patients with advanced-stage Hodgkin lymphoma (HL). The data showed that reducing treatment intensity after a negative PET scan and continuing standard-dose treatment after a positive PET scan was safe and effective over...

Read More

Comparing pembrolizumab and brentuximab vedotin for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma.

Comparing pembrolizumab and brentuximab vedotin for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma.

Posted by on Jun 27, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors compared the safety and effectiveness of pembrolizumab (Keytruda) and brentuximab vedotin (BV; Adcetris) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The study found that pembrolizumab had better survival without cancer worsening compared to BV in these...

Read More

Evaluating the use of high-dose chemotherapy for the treatment of patients with high-risk relapsed Hodgkin lymphoma.

Evaluating the use of high-dose chemotherapy for the treatment of patients with high-risk relapsed Hodgkin lymphoma.

Posted by on Jun 13, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) for the treatment of patients with high-risk relapse (HRR) classical Hodgkin’s lymphoma (cHL). The authors concluded that the outcomes of patients with HRR cHL have improved over the last 15 years with...

Read More

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Posted by on Jun 6, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether brentuximab vedotin (Adcedris; BC) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combination resulted in a reduction or elimination of consolidative radiotherapy in early-stage unfavorable-risk Hodgkin lymphoma (HL). The data showed that the BV+AVD combination with and without...

Read More